PL3113774T3 - Kompozycje grapiprantu i sposoby ich zastosowania - Google Patents

Kompozycje grapiprantu i sposoby ich zastosowania

Info

Publication number: PL3113774T3
Authority: PL; Poland
Prior art keywords: grapiprant; compositions; methods; same
Prior art date: 2014-03-06

Application number

PL15758877T

Other languages

English (en)

Inventor

Lesley Rausch-Derra

Tamara NEWBOLD

Gopinath DEVARAJ

Akemi Shiraishi

Original Assignee

Elanco Animal Health Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-06

Filing date

2015-03-05

Publication date

2022-06-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54016294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3113774(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-05 Application filed by Elanco Animal Health Incorporated filed Critical Elanco Animal Health Incorporated

2022-06-13 Publication of PL3113774T3 publication Critical patent/PL3113774T3/pl

Links

HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical group CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 title 1
229950004517 grapiprant Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL15758877T 2014-03-06 2015-03-05 Kompozycje grapiprantu i sposoby ich zastosowania PL3113774T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201461948957P	2014-03-06	2014-03-06
US201462089713P	2014-12-09	2014-12-09
EP15758877.3A EP3113774B1 (en)	2014-03-06	2015-03-05	Compositions of grapiprant and methods for using the same
PCT/US2015/019037 WO2015134792A1 (en)	2014-03-06	2015-03-05	Compositions of grapiprant and methods for using the same

Publications (1)

Publication Number	Publication Date
PL3113774T3 true PL3113774T3 (pl)	2022-06-13

Family

ID=54016294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15758877T PL3113774T3 (pl)	2014-03-06	2015-03-05	Kompozycje grapiprantu i sposoby ich zastosowania

Country Status (15)

Country	Link
US (4)	US11369621B2 (pl)
EP (1)	EP3113774B1 (pl)
JP (1)	JP6419857B2 (pl)
KR (1)	KR102270323B1 (pl)
CN (2)	CN105939713A (pl)
AU (1)	AU2015227059B2 (pl)
CA (1)	CA2941008C (pl)
DK (1)	DK3113774T3 (pl)
ES (1)	ES2907285T3 (pl)
MX (3)	MX376175B (pl)
PL (1)	PL3113774T3 (pl)
PT (1)	PT3113774T (pl)
RU (1)	RU2679631C2 (pl)
TW (2)	TWI664969B (pl)
WO (1)	WO2015134792A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12109218B2 (en) *	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
TWI664969B (zh) *	2014-03-06	2019-07-11	雅瑞塔那醫療公司	格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法
US20210315909A1 (en)	2018-07-11	2021-10-14	Arrys Therapeutics, Inc.	Polymorphic compounds and uses thereof
CA3113468A1 (en) *	2018-09-27	2020-04-02	Arrys Therapeutics, Inc.	Grapiprant unit dosage forms
WO2021205367A1 (en) *	2020-04-08	2021-10-14	Askat Inc.	Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia
CN117357520A (zh) *	2022-06-29	2024-01-09	瑞普（天津）生物药业有限公司	一种用于伴侣动物骨关节炎镇痛的药物组合物及其应用
US20240342196A1 (en) *	2023-04-13	2024-10-17	The Uab Research Foundation	Targeting select lipid signaling to counter type 1 diabetes (t1d)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DZ2479A1 (fr) *	1997-05-05	2003-02-01	Pfizer	Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
AU6836200A (en) *	1999-08-10	2001-03-05	Glaxo Group Limited	Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
HN2001000224A (es) *	2000-10-19	2002-06-13	Pfizer	Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
WO2003008637A2 (en)	2001-07-17	2003-01-30	Xanthus Life Sciences, Inc.	Use of genotyping in the individualization of therapy
ATE371454T1 (de)	2001-10-31	2007-09-15	Medical Res Council	Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
BR0309200A (pt)	2002-04-12	2005-02-22	Pfizer	Uso de ligandos receptores ep4 no tratamento de doenças envolvidas com a il-6
JP2007533723A (ja)	2004-04-20	2007-11-22	ファイザー・プロダクツ・インク	α２δリガンドを含む組合せ
AU2006221699A1 (en) *	2005-03-11	2006-09-14	Pfizer Inc.	Crystal forms of an imidazole derivative
JP5244091B2 (ja)	2006-04-24	2013-07-24	メルクカナダインコーポレイテッド	Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
US20080242713A1 (en)	2007-03-28	2008-10-02	Bayer Schering Pharma Aktiengesellschaft	Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
CA2789665C (en)	2010-02-22	2020-06-16	Askat Inc.	Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
WO2011124525A1 (de) *	2010-04-08	2011-10-13	Boehringer Ingelheim International Gmbh	Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
JP5990176B2 (ja)	2010-10-12	2016-09-07	メルツファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフトアウフアクティーン	タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
WO2012122279A1 (en)	2011-03-08	2012-09-13	Zalicus Pharmaceuticals Ltd.	Solid dispersion formulations and methods of use thereof
CN103702995B (zh)	2011-05-18	2016-04-13	拉夸里亚创药株式会社	4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
ITBO20110461A1 (it)	2011-07-29	2013-01-30	Alfa Wassermann Spa	Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
KR20150130404A (ko)	2013-03-19	2015-11-23	에스크엣 인크.	연골질환 치료에서의 ep4 수용체 길항제의 용도
CA2997692A1 (en)	2014-03-06	2015-09-11	Aratana Therapeutics, Inc.	Crystalline forms of grapiprant
US12109218B2 (en) *	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
TWI664969B (zh) *	2014-03-06	2019-07-11	雅瑞塔那醫療公司	格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法

2015
- 2015-03-05 TW TW104107084A patent/TWI664969B/zh active
- 2015-03-05 US US14/639,898 patent/US11369621B2/en active Active
- 2015-03-05 AU AU2015227059A patent/AU2015227059B2/en active Active
- 2015-03-05 DK DK15758877.3T patent/DK3113774T3/da active
- 2015-03-05 JP JP2016573691A patent/JP6419857B2/ja active Active
- 2015-03-05 PL PL15758877T patent/PL3113774T3/pl unknown
- 2015-03-05 CN CN201580006168.6A patent/CN105939713A/zh active Pending
- 2015-03-05 ES ES15758877T patent/ES2907285T3/es active Active
- 2015-03-05 CA CA2941008A patent/CA2941008C/en active Active
- 2015-03-05 RU RU2016137926A patent/RU2679631C2/ru active
- 2015-03-05 TW TW106126404A patent/TWI708606B/zh active
- 2015-03-05 WO PCT/US2015/019037 patent/WO2015134792A1/en not_active Ceased
- 2015-03-05 KR KR1020167027433A patent/KR102270323B1/ko active Active
- 2015-03-05 EP EP15758877.3A patent/EP3113774B1/en active Active
- 2015-03-05 MX MX2016011025A patent/MX376175B/es active IP Right Grant
- 2015-03-05 PT PT157588773T patent/PT3113774T/pt unknown
- 2015-03-05 CN CN202011270789.4A patent/CN112370450A/zh active Pending
2016
- 2016-05-02 US US15/144,609 patent/US20160317559A1/en not_active Abandoned
- 2016-08-24 MX MX2020001428A patent/MX2020001428A/es unknown
- 2016-08-24 MX MX2022014763A patent/MX2022014763A/es unknown
2024
- 2024-10-07 US US18/908,587 patent/US12478633B2/en active Active
2025
- 2025-10-30 US US19/374,274 patent/US20260053822A1/en active Pending

Also Published As

Publication number	Publication date
RU2679631C2 (ru)	2019-02-12
RU2019102384A3 (pl)	2022-03-31
CN112370450A (zh)	2021-02-19
CA2941008C (en)	2022-07-26
TWI664969B (zh)	2019-07-11
AU2015227059A1 (en)	2016-09-22
AU2015227059B2 (en)	2018-11-15
JP6419857B2 (ja)	2018-11-07
CA2941008A1 (en)	2015-09-11
US20250025481A1 (en)	2025-01-23
TW201815393A (zh)	2018-05-01
ES2907285T3 (es)	2022-04-22
EP3113774B1 (en)	2022-01-26
WO2015134792A1 (en)	2015-09-11
MX2022014763A (es)	2023-01-11
RU2019102384A (ru)	2019-03-04
DK3113774T3 (da)	2022-03-07
KR102270323B1 (ko)	2021-06-29
JP2017507190A (ja)	2017-03-16
PT3113774T (pt)	2022-02-28
NZ724007A (en)	2021-02-26
MX376175B (es)	2025-03-07
EP3113774A1 (en)	2017-01-11
TW201603812A (zh)	2016-02-01
US20160317559A1 (en)	2016-11-03
TWI708606B (zh)	2020-11-01
RU2016137926A (ru)	2018-04-09
CN105939713A (zh)	2016-09-14
MX2020001428A (es)	2020-03-20
US20150250773A1 (en)	2015-09-10
US20260053822A1 (en)	2026-02-26
NZ761827A (en)	2021-03-26
US11369621B2 (en)	2022-06-28
EP3113774A4 (en)	2017-10-25
US12478633B2 (en)	2025-11-25
MX2016011025A (es)	2016-11-29
KR20160129887A (ko)	2016-11-09

Publication	Publication Date	Title
ZA201701244B (en)	2018-05-30	Carrier-antibody compositions and methods of making and using the same
GB2535253B (en)	2019-04-17	Compositions and methods
GB2546350B (en)	2019-12-04	Compositions and methods
SG10202109655VA (en)	2021-10-28	Compositions and methods for immunooncology
GB2535423B (en)	2021-06-23	Cementing compositions and methods
HUE056172T2 (hu)	2022-01-28	Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
GB201718876D0 (en)	2017-12-27	Antithrombin-heparin compositions and methods
IL246879B (en)	2020-05-31	Preparations of Epilimod and methods of using them
ZA202104969B (en)	2023-01-25	Compositions comprising 15-hepe and methods of using the same
GB201417828D0 (en)	2014-11-19	New methods and compositions
EP3166892A4 (en)	2018-03-14	Scale-inhibition compositions and methods of making and using the same
SG11201608128UA (en)	2016-11-29	Polishing composition and polishing method
PT3113774T (pt)	2022-02-28	Composições de grapiprant e métodos de utilização das mesmas
GB201715820D0 (en)	2017-11-15	Compositions and methods
GB201705626D0 (en)	2017-05-24	Compositions and methods
ZA201606594B (en)	2018-11-28	Defoamer compositions and methods of using the same
ZA201807665B (en)	2020-02-26	Methods and compositions
EP3207029A4 (en)	2018-05-02	Tryptamide compositions and methods of use
GB201512996D0 (en)	2015-09-09	Compositions and methods
EP3221366A4 (en)	2018-05-23	Polyaminomethylbenzyloxalamides and compositions and methods related thereto
GB201514413D0 (en)	2015-09-30	Compositions and methods
GB201402915D0 (en)	2014-04-02	Compositions and methods
ZA201807782B (en)	2020-05-27	Methods and compositions
IL256261B (en)	2022-06-01	Hide1 compositions and methods
GB201403212D0 (en)	2014-04-09	Compositions and methods